• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Genprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8/4/25 8:38:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    gnpx20250618d_8k.htm
    false 0001595248 0001595248 2025-08-04 2025-08-04
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549 
       
     
     
    FORM 8-K
        
     
     
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
     
    August 4, 2025
    Date of report (Date of earliest event reported)
     
    GENPREX, INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-38244
    90-0772347
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File Number)
    (I.R.S. Employer
    Identification Number)
         
    3300 Bee Cave Road, #650-227, Austin, TX
     
    78746
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (512) 537-7997
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, par value $0.001 per share
     
    GNPX
     
    The Nasdaq Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 7.01 Regulation FD Disclosure.
     
    Press Release & Stockholder Update
     
    On August 4, 2025, Genprex, Inc. (the “Company”) issued a press release announcing the issuance of a stockholder letter and corporate update. The full text of the press release and the stockholder letter and corporate update is attached to this Current Report on Form 8-K as Exhibit 99.1. The press release including stockholder letter and corporate update that is furnished as Exhibit 99.1 to this Current Report on Form 8-K will be available on the Company’s website, www.genprex.com.
     
    The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.
     
    Item 9.01 Financial Statements and Exhibits.
     
    (d) Exhibits.
     
    Exhibit
    Number
     
     Description
         
    99.1   Press Release dated August 4, 2025, issued by Genprex, Inc.
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    GENPREX, INC.
     
           
    Date: August 4, 2025
    By:
    /s/ Ryan Confer
     
       
    Ryan Confer
     
       
    President, Chief Executive Officer and Chief Financial Officer
    (Principal Executive Officer and Principal Financial and Accounting Officer)
     
     
     
    Get the next $GNPX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    National Securities initiated coverage on Genprex with a new price target

    National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

    1/26/21 7:48:53 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $GNPX
    SEC Filings

    View All

    Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

    Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, Sept. 2, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences being held in September 2025. Event: H.C. Wainwright 27th Annual Global Investment ConferenceLocation: Lotte New York Palace Hotel, New York CityConference Dates: September

    9/2/25 8:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

    Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®. Similarly, the European Patent Office has issued a Notice of Allowance to Genprex for a patent covering the use of

    8/18/25 9:29:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

    Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas, Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a stockholder letter and corporate update summarizing the Company's recent achievements across its oncology and diabetes programs and outlines key milestones for 2025 and beyond. "Genprex has m

    8/4/25 8:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 4,500 shares, decreasing direct ownership by 20% to 17,971 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    7/1/25 5:52:13 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 5,775 shares, decreasing direct ownership by 15% to 32,968 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    7/1/25 5:51:04 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 585 shares, decreasing direct ownership by 3% to 22,471 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/19/25 8:01:36 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Genprex Inc.

    S-1 - Genprex, Inc. (0001595248) (Filer)

    9/12/25 4:46:01 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    8/20/25 4:16:08 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    8/18/25 9:29:35 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

    Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

    5/13/24 8:31:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

    Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

    8/22/23 7:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Genprex Inc.

    SC 13G/A - Genprex, Inc. (0001595248) (Subject)

    10/24/24 12:23:37 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/22/24 12:01:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/3/24 10:09:50 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care